Literature DB >> 19459159

Alpha-methylacyl-CoA racemase (AMACR) in fine-needle aspiration specimens of prostate lesions.

Gordana Kaić1, Cedna Tomasović-Loncarić.   

Abstract

The elevated expression of P504S gene and its product alpha-methylacyl-CoA racemase (AMACR) can serve as a molecular marker for prostate cancer. The goal of this study is to investigate P504S/AMACR expression in fine-needle aspiration smears and correlate it with cytological diagnosis. Immunocytochemistry was performed in 35 patients with morphological diagnosis of prostate carcinoma (n = 16), atypia (n = 15), and benign hyperplasia (n = 4). Among 16 malignant cases there were two low-grade, eight intermediate, and six high-grade prostate carcinomas. Cytoplasmic positivity is analyzed qualitatively as predominantly diffuse or focal and quantitatively as <5%, 5-50%, and >50% of cells. Benign cases showed no P504S/AMACR expression. Positive staining was recorded in 75% of malignant cases, but in the majority of them it was weak and focal or diffuse and in a small amount of cells. The most intensive staining was seen in low-grade carcinomas and some atypical cases. This observation indicates a correlation between P504S/AMACR expression and differentiation of cells. P504S/AMACR staining might be of great value in cytodiagnosis of prostate lesions as well as an example of the characterization of cells at the molecular level using fresh tissue obtained by fine-needle aspiration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19459159     DOI: 10.1002/dc.21103

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  7 in total

1.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

2.  High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.

Authors:  Yanling Zhang; Xue-Ying Mao; Xiaoyan Liu; Rong-Rong Song; Daniel Berney; Yong-Jie Lu; Guoping Ren
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Diagnostic Value of Cytokeratin 34 beta E12 (Ck34βE12) and α-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions.

Authors:  Ikram A Hasan; Hiba Ahmed Gaidan; Methaq Mueen Al-Kaabi
Journal:  Iran J Pathol       Date:  2020-05-21

4.  Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.

Authors:  Diana Taheri; Elham Roohani; Mohammad Hossein Izadpanahi; Shahaboddin Dolatkhah; Farshad Aghaaliakbari; Parnaz Daneshpajouhnejad; Mohammad Reza Gharaati; Hamid Mazdak; Shahriar Fesharakizadeh; Yasasmin Beinabadi; Reza Kazemi; Mahtab Rahbar
Journal:  J Res Med Sci       Date:  2021-07-31       Impact factor: 1.852

5.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

6.  The expressions of AMACR and iNOS in prostate adenocarcinomas.

Authors:  Tumay Ozgur; Esin Atik; Sibel Hakverdi; Mehmet Yaldiz
Journal:  Pak J Med Sci       Date:  2013-04       Impact factor: 1.088

7.  A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.

Authors:  Ning Jiang; Shimiao Zhu; Jing Chen; Yuanjie Niu; Liqun Zhou
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.